Text Size Normal Text Sizing Button Medium Text Sizing Button Large Text Sizing Button Text Contrast Normal Contrast Button Reverse Contrast Button Switch to Spanish Language Press Room Contact Us Sitemap Sign In Register
Link to Homepage About BrightFocus
Donate Now Get Involved  
Alzheimer's Disease Research Macular Degeneration Research National Glaucoma Research

Sign up for Email Notifications
If you would like to be notified when funding or meeting opportunities are announced please click on the link below.

Sign up for new announcements.

Please add ResearchGrants@BrightFocus.org to your institution’s white list to insure that the notification is not blocked by your organization’s SPAM filters.

This email list is not sold or distributed, and serves only as an annual reminder of the availability of research support through the BrightFocus Foundation (www.brightfocus.org). Please follow instructions on the notification emails for removal requests.

BrightFocus Research Grants Funding
Grant Funding for Alzheimer's Research
Grant Funding for Macular Degeneration Research
Grant Funding for Glaucoma Research


Alzheimer's Disease Research
Completed Award

Dr. Michael DeTure

Michael DeTure, Ph.D.

Mayo Clinic Jacksonville
Jacksonville, FL, United States

Title: Restoration of the 3R:4R Tau Equilibrium as a Tauopathy Therapy
Non-Technical Title: Restoration of the 3R:4R Tau Equilibrium as an Alzheimer Therapy

Duration: July 1, 2011 - June 30, 2013
Award Type: Pilot
Award Amount: $150,000


Tau polymerization into neurofibrillary tangles is a central pathological feature of Alzheimer's disease as the abundance of these lesions correlates positively with neuronal loss and cognitive decline in these patients. Tau based neurodegeneration may be caused directly by altering the normal equimolar 3R to 4R tau ratio; and indeed, different silent mutations in tau have been shown to lead to the preferential expression and accumulation of either 3R or 4R tau with resulting neuronal loss and cognitive decline in FTDP-17. Together these results suggest that therapeutic interventions aimed at returning the tau isoform ratios to their normal balance may benefit tauopathy patients including AD patients which also exhibit locally enriched 3R or 4R tau deposits.


Two hallmarks of Alzheimer's disease are plaques and tangles—protein deposits in the brain that can lead to nerve cell death and memory problems. Tangles are formed when a certain type of protein, called tau, becomes sticky and forms messy blobs inside of nerve cells. Dr. Michael DeTure and collaborators think that tangles are formed when the natural balance of two versions of tau tip to the sticky form, and that by setting the balance straight again they can prevent tangles from forming. In this project, they will genetically increase the expression levels of the non‐sticky form of tau in a mouse model of Alzheimer's. This should restore the balance of the ratios and perhaps prevent the tangles from forming. If they do find a way to restore the balance of tau expression, then this could be an exciting new treatment to block or reverse the formation of tangles in individuals with Alzheimer's disease.

Progress Updates:

This past year, in an effort to determine if restoring this equilibrium can slow the disease, Dr. DeTure’s team has constructed expression vectors for 3R and 4R tau protein. The team is preparing to determine if they can prevent or reverse disease caused by over-expression of 4R tau. This would provide the first direct evidence that restoring this delicate balance can ameliorate the disease, and it would represent a new point for therapeutic intervention in Alzheimer's disease.

Investigator Biography:

Dr. Michael DeTure is an assistant professor in the Department of Neuroscience at the Mayo Clinic campus in Jacksonville Florida. He completed his doctoral training at the University of Florida where he studied the assembly properties of tau proteins which cause neuronal loss in Alzheimer's disease. He did his post doctoral studies at the Mayo Clinic Jacksonville as a Smith Fellow in Neuroscience. There he examined the pathogenic effects of tau mutations on assembly and how these can be used to model Alzheimer pathology in cell culture systems and animal models. His current research at the Mayo Clinic is focused on further refinement of these models systems and how they can be used to develop therapeutic approaches that enhance the clearance of pathologic tau species and prevent their assembly.